title: Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.
abstract: Up-regulation of arginase activity in several chronic disease conditions, including cancer and hypertension, may suggest new targets for treatment. Recently, the number of new arginase inhibitors with promising therapeutic effects for asthma, cancer, hypertension, diabetes mellitus, and erectile dysfunction has shown a remarkable increase. Arginase inhibitors may be chemical substances, such as boron-based amino acid derivatives, α-difluoromethylornithine (DMFO), and Nω-hydroxy-nor-L-arginine (nor-NOHA) or, of plant origin such as sauchinone, salvianolic acid B (SAB), piceatannol-3-O-β-D-glucopyranoside (PG) and obacunone. Despite their promising therapeutic potential, little is known about pharmacokinetics and pharmacodynamics of some of these agents. Several studies were conducted in different animal species and in vitro systems and reported significant differences in pharmacokinetics and pharmacodynamics of arginase inhibitors. Therefore, extra caution should be considered before extrapolating these studies to human. Physicochemical and pharmacokinetic profiles of some effective arginase inhibitors make it challenging to formulate stable and effective formulation. In this article, existing literature on the pharmacokinetics and pharmacodynamics of arginase inhibitors were reviewed and compared together with emphasis on possible drug interactions and solutions to overcome pharmacokinetics challenges and shortage of arginase inhibitors in clinical practice.
authors.affiliation: Faculty of Pharmacy, Kafrelsheikh University, Kafr El-Sheikh, Egypt.
authors.forename: Khaled S
authors.initials: KS
authors.lastname: Abdelkawy
authors.affiliation: School of Pharmacy, Pacific University, 222 SE 8th Ave., Hillsboro, OR, 97123, USA.
authors.forename: Kelsey
authors.initials: K
authors.lastname: Lack
authors.affiliation: School of Pharmacy, Pacific University, 222 SE 8th Ave., Hillsboro, OR, 97123, USA. Fawzy.elbarbry@pacificu.edu.
authors.forename: Fawzy
authors.initials: F
authors.lastname: Elbarbry
mesh_terms: D000818:Animals; D001119:Arginase / Q000037:antagonists & inhibitors*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004347:Drug Interactions / Q000502:physiology; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006801:Humans
chemical_list: D004791:Enzyme Inhibitors; D001119:Arginase